Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
21 studies found for:    cantos
Show Display Options
Rank Status Study
1 Active, not recruiting Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Condition: Atherosclerosis
Interventions: Drug: Canakinumab;   Drug: Placebo
2 Recruiting Breast Cancer Toxicity
Condition: Breast Cancer Nos Metastatic Recurrent
Intervention: Procedure: blood sampling
3 Active, not recruiting Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)
Conditions: Prior Acute Myocardial Infarction;   Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l);   Reduced Left Ventricle Ejection Fraction (<50%);   Symptoms of Heart Failure (NYHA Class II-III)
Interventions: Other: Cardiopulmonary exercise test;   Other: Echocardiogram
4 Recruiting Predicting Risk of Cancer in Barrett's Esophagus
Conditions: Barrett Esophagus;   Esophageal Neoplasm;   Gastroesophageal Reflux
5 Recruiting Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System
Condition: Barrett Esophagus
Intervention: Device: CryoBalloon Ablation System
6 Active, not recruiting Safety and Efficacy Evaluation of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With AMI
Condition: Acute Myocardial Infarction
Interventions: Other: Allogeneic human cardiac stem cells (CSCs);   Other: Human Serum Albumin-HSA 5%
7 Unknown  Assesment of a Predictive Model Dosage of EPO in Hemodialysis Patients
Condition: Anemia
8 Unknown  Autologous Stem Cells Derived From Lipoaspirates for the Non-Surgical Treatment of Complex Perianal Fistula
Condition: Anal Fistula
Intervention: Procedure: Non-surgical autologous implant of ASCs
9 Enrolling by invitation International CAPS Registry: Pancreas Cancer Cases in Surveillance Programs
Condition: Pancreas Cancer
10 Completed Confocal Endomicroscopy for Improved Diagnosis of Barrett's Esophagus and Early Esophageal Cancer(CEBE Study)
Condition: Barrett's Esophagus, Esophageal Intraepithelial Neoplasia
Intervention: Procedure: endomicroscopy
11 Enrolling by invitation Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Epithelium
Conditions: Barrett's Esophagus;   Esophageal Squamous Dysplasia;   Esophageal Cancer
Intervention: Device: CryoBalloon
12 Unknown  ISM1 Versus EmbrioGen Media for Embryo Culture With Previous Failure Implantation in ART Treatments
Conditions: Infertility;   Implantation Failure
13 Unknown  Ism1 Versus EmbryoGen Media for Embryo Culture in Previous Pregnancy Loss Cases
Conditions: Infertility;   Miscarriage
14 Completed
Has Results
Confocal Endomicroscopy for Barrett's Esophagus
Conditions: Barrett's Esophagus;   Esophageal Adenocarcinoma
Interventions: Device: confocal laser endomicroscopy (CLE);   Device: standard endoscopy (EGD)
15 Completed Cancer of the Pancreas Screening Study (CAPS 3)
Conditions: Pancreatic Neoplasm;   Peutz-Jeghers Syndrome
Interventions: Procedure: Biopsy, Fine Needle Aspiration (FNA);   Drug: Secretin (human synthetic) - ChiRhoClin
16 Completed Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study)
Conditions: Early Pancreatic Neoplasia;   Familial Pancreatic Neoplasia
17 Completed Spanish Validation Of Quality of Life Questionnaire (QOLIE-10) For Epilepsy
Condition: Epilepsy
Interventions: Drug: lamotrigine;   Drug: valproic acid
18 Recruiting Familial Barrett's Esophagus
Conditions: Barrett's Esophagus;   Esophageal Neoplasm
19 Completed The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Condition: Colorectal Cancer
Interventions: Drug: Methylene Blue MMX®;   Drug: Placebo
20 Completed Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Paclitaxel 80 mg/m2;   Drug: Nab-paclitaxel 100 mg/m2 days 1, 8 and 15;   Drug: Nab-paclitaxel 150 mg/m2 days 1, 8 and 15;   Drug: Nab-paclitaxel 150 mg/m2 days 1 and 15

   Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.